Opinion|Videos|April 10, 2026
Treatment Adhereance and AE Management With Sevabertinib in HER2-Mutant NSCLC
Author(s)Martin Dietrich, MD, PhD, Ticiana A. Leal, MD
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss toxicity management with TKIs in HER2-mutant non–small cell lung cancer.
Advertisement
Episodes in this series
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss strategies to optimize adherence and manage adverse effects associated with HER2-targeted TKIs. Dietrich outlines common toxicities and the need for proactive monitoring and early intervention. Leal highlights the role of dose modifications and patient education in maintaining treatment continuity and maximizing therapeutic benefit.
Advertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5